MARKET

BIOA

BIOA

BioAge Labs Inc.
NASDAQ
7.14
-0.04
-0.56%
After Hours: 7.36 +0.22 +3.08% 19:30 09/29 EDT
OPEN
7.19
PREV CLOSE
7.18
HIGH
7.27
LOW
7.07
VOLUME
425.33K
TURNOVER
--
52 WEEK HIGH
25.96
52 WEEK LOW
5.04
MARKET CAP
327.70M
P/E (TTM)
-2.9932
1D
5D
1M
3M
1Y
5Y
1D
BioAge Therapeutics: Buy Rating Reiterated with Compelling 198% Upside and Maintained $21 Price Target on Inflammation-Targeted Retinal Therapy Validation
TipRanks · 18h ago
Weekly Report: what happened at BIOA last week (0921-0925)?
Weekly Report · 1d ago
BioAge Labs to Present at Upcoming Investor Conferences
Barchart · 4d ago
Weekly Report: what happened at BIOA last week (0914-0918)?
Weekly Report · 09/21 10:20
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Seeking Alpha · 09/18 14:20
Analysts Offer Insights on NA Companies: Fair Isaac (FICO), Freeport-McMoRan (FCX) and BioAge Labs, Inc. (BIOA)
TipRanks · 09/14 11:10
Weekly Report: what happened at BIOA last week (0907-0911)?
Weekly Report · 09/14 10:25
Analysts’ Top NA Picks: BioAge Labs, Inc. (BIOA), OS Therapies Incorporated (OSTX)
TipRanks · 09/09 11:50
More
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

Webull offers BioAge Labs, Inc. stock information, including NASDAQ: BIOA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIOA stock methods without spending real money on the virtual paper trading platform.